Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP4 | P15090 | 1/20 | 0.58 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.49 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.47 |
| ▸ | PARP1 | P09874 | 3/20 | 0.46 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.46 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.44 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.44 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.44 |
| ▸ | TAS2R14 | Q9NYV8 | 2/20 | 0.42 |
| ▸ | IKBKB | O14920 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.41 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.41 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.41 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30339795 | 1.00 | FABP4 (0.58) | FABP4BCAT2PDK2PARP1NR1H2 | |
| Hydrochloric Acid SCHEMBL28812647 | 0.98 | FABP4 (0.57) | FABP4BCAT2PDK2PARP1NR1H2 | |
| SCHEMBL6703940 | 0.86 | FABP4 (0.70) | FABP4NR1H2NR1H3LMNAGAA | |
| SCHEMBL4846678 | 0.86 | FABP4 (0.61) | FABP4NR1H2NR1H3LMNAGAA | |
| SCHEMBL5131387 | 0.86 | FABP4 (0.45) | FABP4PDK2PARP1LMNAGAA | |
| SCHEMBL30241242 | 0.86 | FABP4 (0.45) | FABP4PDK2PARP1NR1H2NR1H3 | |
| SCHEMBL31304715 | 0.83 | FABP4 (0.58) | FABP4NR1H2NR1H3LMNAGAA | |
| Trifluoroacetic Acid SCHEMBL18049957 | 0.83 | BCAT2 (0.52) | FABP4BCAT2PDK2PARP1KEAP1 | |
| SCHEMBL4555401 | 0.83 | FABP4 (0.46) | FABP4BCAT2PDK2PARP1NR1H2 | |
| SCHEMBL29427280 | 0.82 | SCN5A (0.49) | PARP1SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10344032-B2 | Agents for treating neurogenic inflammation and neuropathic hyperalgesia related disorders | PÉCSI TUDOMÁNYEGYETEM (HU) | 2019-07-09 | — | — | US | claimed |
| EP-3194399-B1 | NEW AGENTS FOR TREATING NEUROGENIC INFLAMMATION AND NEUROPATHIC HYPERALGESIA RELATED DISORDERS | PECSI TUDOMANYEGYETEM (HU) | 2019-04-10 | — | — | EP | claimed |
| US-20170260187-A1 | NEW AGENTS FOR TREATING NEUROGENIC INFLAMMATION AND NEUROPATHIC HYPERALGESIA RELATED DISORDERS | PÉCSI TUDOMÁNYEGYETEM (HU) | 2017-09-14 | — | — | US | claimed |
| EP-3194399-A1 | NEW AGENTS FOR TREATING NEUROGENIC INFLAMMATION AND NEUROPATHIC HYPERALGESIA RELATED DISORDERS | Pécsi Tudományegyetem (HU) | 2017-07-26 | — | — | EP | claimed |
| WO-2016042349-A1 | NEW AGENTS FOR TREATING NEUROGENIC INFLAMMATION AND NEUROPATHIC HYPERALGESIA RELATED DISORDERS | PÉCSI TUDOMÁNYEGYETEM (HU) | 2016-03-24 | — | — | WO | claimed |
| WO-2012014127-A1 | 5-LIPOXYGENASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2012-02-02 | — | — | WO | claimed |
| EP-1928843-A1 | BIS-ARYL UREA COMPOUNDS FOR THE TREATMENT OF PROTEIN KINASE-MEDIATED DISEAES | Amgen, Inc (US) | 2008-06-11 | — | — | EP | claimed |
| WO-2007024754-A1 | BIS-ARYL UREA COMPOUNDS FOR THE TREATMENT OF PROTEIN KINASE-MEDIATED DISEAES | AMGEN INC. (US) | 2007-03-01 | — | — | WO | claimed |
| WO-2005073193-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2005-08-11 | — | — | WO | claimed |
| CN-1155278-A | Arylthio compounds as antibacteral and antiviral agents | WARNER LAMBERT CO (US) | 1997-07-23 | — | — | CN | claimed |
| EP-4211230-A1 | COMPOSITIONS AND METHODS FOR T CELL ENGINEERING | Gracell Biotechnologies (Shanghai) Co., Ltd. (CN) | 2023-07-19 | — | — | EP | disclosed |
| WO-2023104155-A1 | LIGAND COMPOUNDS FOR E3 UBIQUITIN LIGASE, PROTEIN DEGRADERS DEVELOPED ON BASIS OF LIGAND COMPOUNDS, AND USES THEREOF | 标新生物医药科技(上海)有限公司 | 2023-06-15 | — | — | WO | disclosed |
| CN-110272426-B | Alkynyl (hetero) aromatic ring compounds for inhibiting protein kinase activity | 深圳市塔吉瑞生物医药有限公司 | 2022-05-31 | — | — | CN | disclosed |
| WO-2022052913-A1 | COMPOSITIONS AND METHODS FOR T CELL ENGINEERING | GRACELL BIOTECHNOLOGIES (SHANGHAI) CO., LTD. (CN) | 2022-03-17 | — | — | WO | disclosed |
| WO-2021223705-A1 | COMPOSITIONS AND METHODS FOR T CELL ENGINEERING | GRACELL BIOTECHNOLOGIES (SHANGHAI) CO., LTD. (CN) | 2021-11-11 | — | — | WO | disclosed |
| EP-1681924-A1 | BIPHENYL DERIVATIVE OR ITS SALT, AND PESTICIDE CONTAINING IT AS AN ACTIVE INGREDIENT | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2006-07-26 | — | — | EP | disclosed |
| EP-1532138-A1 | INHIBITORS OF TYROSINE KINASES | Novartis AG (CH) | 2005-05-25 | — | — | EP | disclosed |
| WO-2005044007-A1 | BIPHENYL DERIVATIVE OR ITS SALT, AND PESTICIDE CONTAINING IT AS AN ACTIVE INGREDIENT | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2005-05-19 | — | — | WO | disclosed |
| WO-2004005281-A1 | INHIBITORS OF TYROSINE KINASES | NOVARTIS AG (CH) | 2004-01-15 | — | — | WO | disclosed |
| CN-1308604-A | 2,3,5-substituted biphenyls useful in the treatment of insulin resistance and hyperglycemia | AMERICAN HOME PROD (US) | 2001-08-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10344032-B2 | Agents for treating neurogenic inflammation and neuropathic hyperalgesia related disorders | TRPV1, P2RX3, P2RX7 | FABP4 1108/4885BCAT2 3026/4885PDK2 974/4885 |
| US-20170260187-A1 | NEW AGENTS FOR TREATING NEUROGENIC INFLAMMATION AND NEUROPATHIC HYPERALGESIA RELATED DISORDERS | TRPV1, P2RX3, P2RX4 | FABP4 1696/4885BCAT2 3248/4885PDK2 1406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.